New Delhi, Jan 20 (IANS) Bengaluru-based cell and gene therapy start-up Immuneel Therapeutics on Monday announced the launch of Qartemi — the country’s first personalised and precision therapy CAR T-cell therapy for treating B-cell Non-Hodgkin Lymphoma (B-NHL) in adults.
B-cell non-Hodgkin lymphoma (B-NHL) is a type of blood cancer that affects the B cells in the lymphatic system. B-NHL is the most common type of non-Hodgkin lymphoma (NHL) in India, accounting for 80-85 per cent of all cases.
Qartemi, approved by the Indian regulator the Central Drugs Standard Control Organisation(CDSCO), provides a personalised therapy for adult patients with relapsed or refractory B-NHL. It has also received license from Spain’s Hospital Clinic de Barcelona (HCB), a globally renowned institution at the forefront of cell therapy innovation.
Developed indigenously in Bengaluru, Qartemi (varnimcabtagene autoleucel – IMN-003A) harnesses a patient’s immune cells to target and eliminate cancer, offering new hope to those battling aggressive blood cancers. It has shown a potential to provide lasting remission of relapsed and refractory NHL, even when conventional therapies including chemotherapy prove ineffective.
Notably, it is priced at one-tenth the cost of a similar product in the US, the company said.
“Since Immuneel’s inception in 2019, our mission has been to offer affordable and innovative, lifesaving therapies for cancer that are otherwise inaccessible,” Kiran Mazumdar-Shaw, Board Director & Co-Founder, Immuneel Therapeutics.
“With Qartemi, our flagship CAR T-cell therapy, we aim to transform cancer treatment in India by providing globally advanced, personalised therapies at an affordable cost,” added Mazumdar-Shaw.
Immuneel, launched in 2019, initiated the trial on India’s first CAR T-cell therapy trial in 2022 for a novel autologous CD19-directed CAR-T cell therapy in patients with relapsed / refractory B cell malignancies. The trial was conducted across various hospitals including PGIMER in Chandigarh, and others in Bengaluru, and Chennai.
The CD19-directed, genetically modified autologous chimeric antigen receptor T-cell immunotherapy involves modifying a patient’s T-cells to specifically target and destroy cancer cells. Data from clinical trials in India and Spain show that the safety and efficacy of Qartemi is similar to that of CAR T-cell therapies approved by the USFDA.
“The launch of Qartemi marks a pivotal moment in India’s fight against cancer. By combining world-class research CAR-T cell therapy with indigenous manufacturing, we are offering new hope to patients facing aggressive blood cancers,” said Dr. Siddhartha Mukherjee, Board Director & Co-Founder, Immuneel Therapeutics.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
